Posaconazole

證據等級: L5

預測適應症: 1 個

Posaconazole: From Invasive Fungal Infection Prophylaxis to Pneumocystosis

One-Sentence Summary

Posaconazole is a triazole antifungal currently used as broad-spectrum prophylaxis against invasive fungal infections (Aspergillus, Candida, Mucorales) in immunocompromised and transplant patients. The TxGNN model predicts it may also be effective for Pneumocystosis (Pneumocystis jirovecii pneumonia), but this direction is currently supported only by 2 indirectly relevant clinical trials and 5 background literature references — none of which directly test posaconazole against Pneumocystis.

Quick Overview

Item	Content
Original Indication	Prophylaxis of invasive fungal infections (Aspergillus, Candida, Mucorales) in immunocompromised/transplant patients (derived from repurposing rationale; official label text not available)
Predicted New Indication	Pneumocystosis (Pneumocystis jirovecii pneumonia)
TxGNN Prediction Score	99.77%
Evidence Level	L4
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is not available in the source label/DrugBank record for this evidence pack. Based on known pharmacology, posaconazole is a triazole antifungal that inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis in fungal cell membranes. It is currently used as broad-spectrum antifungal prophylaxis in hematology/transplant patients, covering Aspergillus, Candida, and Mucorales species.

However, the mechanistic link to Pneumocystosis is weak. Pneumocystis jirovecii is an atypical fungus with very low membrane ergosterol content and a synthesis pathway that differs substantially from typical filamentous/yeast fungi, so triazole antifungals have limited direct evidence of fungicidal activity against it. Posaconazole’s clinical role today is prophylactic coverage of other mold/yeast pathogens in transplant and hematologic malignancy patients — it is not first-line therapy for PJP (which remains TMP-SMX).

The predicted association therefore appears to arise from indication co-occurrence in high-risk immunocompromised/transplant populations (where posaconazole prophylaxis and PJP risk overlap clinically) rather than from a direct pharmacological mechanism against Pneumocystis. This is an indirect, inferential link rather than established antifungal activity evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04368559	Phase 3	Completed	602	Rezafungin (an echinocandin, not posaconazole) vs. standard antimicrobial regimen for prevention of invasive fungal disease in allogeneic HSCT recipients. Relevance grade C — different drug class, disease-domain background only.
NCT06859424	Phase 2	Recruiting	358	Platform trial comparing GVHD prophylaxis regimens after mismatched unrelated donor PBSCT; may include antifungal prophylaxis (potentially posaconazole) as supportive care, but not designed to evaluate posaconazole for pneumocystosis specifically. Relevance grade C — indirect.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41232547	2025	Review/Guideline	The Lancet. Infectious Diseases	UK best-practice update on diagnosis of serious fungal diseases (diagnostic methods, not posaconazole-specific treatment evidence).
41362140	2025	Guideline	Zhonghua Jie He He Hu Xi Za Zhi	Chinese 2025 clinical practice guideline for diagnosis/management of invasive pulmonary fungal disease.
26901377	2016	Review	Swiss Medical Weekly	Overview of invasive candidiasis, aspergillosis, cryptococcosis, and PJP; notes posaconazole’s established role as mould-active prophylaxis reducing invasive candidiasis in high-risk hemato-oncology patients (not direct PJP treatment data).
21973267	2011	Review (PK/PD)	Clinical Pharmacokinetics	Pulmonary epithelial lining fluid penetration of antifungal/antitubercular agents — pharmacokinetic background only.
35596686	2022	Cohort/Case series	Transplant Infectious Disease	Infectious complications (including fungal) in acute GVHD after liver transplant; general infection epidemiology, not posaconazole-PJP specific.

US Market Information

Currently no marketing authorizations recorded for this drug in the reference jurisdiction dataset (market status: Not Marketed, 0 licenses on file).

Safety Considerations

Please refer to the package insert for safety information.

Note: Warning labels, contraindications, and drug-drug interaction data are flagged as outstanding data gaps (including a blocking gap for TFDA label warnings/contraindications) and could not be sourced for this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: No clinical trial or literature evidence directly evaluates posaconazole for pneumocystosis — all available trials/publications are indirect background references (different drug class, general infection epidemiology, or diagnostic guidelines). The mechanistic rationale itself is characterized as inferential rather than established, and posaconazole is not currently marketed in the reference jurisdiction, further limiting near-term actionability.

To proceed, the following is needed:

Resolve blocking safety data gap: TFDA (or equivalent) label warnings/contraindications for posaconazole
Obtain detailed mechanism of action (MOA) documentation from DrugBank/label to support or refute the mechanistic hypothesis
Identify or commission a clinical study directly testing posaconazole efficacy against Pneumocystis jirovecii (current evidence base has no direct trials)
Clarify market/regulatory pathway status, since the drug currently has no license record in this jurisdiction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.